Skip to Content

Erythromycin Oral Products (Abbott Brand Only)

Last Updated: April 21, 2011
Status: Resolved

Products Affected - Description

Arbor Pharmaceuticals has acquired multiple products from Abbott and has transitioned to new NDC numbers. Arbor is now the sole supplier of erythromycin oral products and oral erythromycin is not in short supply.

Erythromycin base – New NDC Numbers

  • 250 mg Filmtab, 100 count (former Abbott NDC 00074-6326-13) – New (NDC 24338-0102-13)
  • 500 mg Filmtab, 100 count (former Abbott NDC 00074-6227-13) – New (NDC 24338-0104-13)
  • 333 mg PCE Dispertab (particles in tablets), 60 count (former Abbott NDC 00074-6290-60) – New (NDC 24338-0112-60)
  • 500 mg PCE Dispertab (particles in tablets), 100 count (former Abbott NDC 00074-3389-13) – New (NDC 24338-0114-13) 
  • Delayed Release Products
    • 250 mg capsules, 100 count (former Abbott NDC 00074-6301-13) – New (NDC 24338-0120-13)
    • 250 mg Ery-Tab, 100 count (former Abbott NDC 00074-6304-13) – New (NDC 24338-0122-13)
    • 333 mg Ery-Tab, 100 count (former Abbott NDC 00074-6320-13) – New (NDC 24338-0124-13)
    • 500 mg Ery-Tab, 100 count (former Abbott NDC 00074-6321-13) – New (NDC 24338-0126-13)

Erythromycin base - Discontinued Abbott products (not acquired by Arbor)

  • Erythromycin Base Filmtab, 250 mg tablets, 500 count (NDC 00074-6326-53) - discontinued
  • Erythromycin Delayed-Release, 250 mg capsules, 500 count (NDC 00074-6301-53) - discontinued
  • Ery-Tab (erythromycin delayed-release), 250 mg tablets, 500 count (NDC 00074-6304-53) - discontinued
  • Ery-Tab (erythromycin delayed-release), 333 mg tablets, 500 count (NDC 00074-6320-53) - discontinued

 Erythromycin ethylsuccinate – New NDC Numbers

  • 400 mg tablets, 100 count (former Abbott NDC 00074-2589-13) – New (NDC 24338-0110-13)
  • 400 mg E.E.S. Filmtab, 100 count (former Abbott NDC 00074-5729-13) – New (NDC 24338-0100-13)
  • 400 mg/5mL EryPed oral suspension, 100 mL (former Abbott NDC 00074-6305-13) – New (NDC 24338-0130-13)
  • 200 mg/5 mL EryPed oral suspension, 100 mL (former Abbott NDC 00074-6302-13) – New (NDC 24338-0132-13)
  • 200 mg/5 mL E.E.S. granules for oral suspension, 100 mL (former Abbott NDC 00074-6369-02) – New (NDC 24338-0134-02)
  • 200 mg/5 mL E.E.S. granules for oral suspension ,200 mL (former Abbott NDC 00074-6369-10) – New (NDC 24338-0136-10)

Erythromycin ethylsuccinate – Discontinued Abbott products (not acquired by Arbor)

  • EES 400 mg Filmtab, 500 count (NDC 00074-5729-53) - discontinued
  • EES 400 mg Filmtab, 1000 count (NDC 00074-5729-19) - discontinued
  • EES 400 mg Filmtab, 100 count, unit dose (NDC 00074-5729-11) - discontinued
  • EES 200 Liquid, 1 pint (NDC 00074-6306-16) - discontinued
  • EES 200 Liquid, 100 mL (NDC 00074-6306-13) - discontinued
  • EES 400 Liquid, 1 pint (NDC 00074-6373-16) - discontinued
  • EES 400 Liquid, 100 mL (NDC 00074-6373-13) - discontinued
  • EryPed for oral suspension, 200 mg/5 mL, 5 mL unit dose, 100 count (NDC 00074-6302-05) - discontinued
  • EryPed oral suspension, 200 mg/5 mL, 200 mL (NDC 00074-6302-53) - discontinued
  • EryPed for oral suspension, 400 mg/5 mL, 5 mL unit dose, 100 count (NDC 00074-6305-05) - discontinued
  • EryPed for oral suspension, 400 mg/5 mL, 60mL (NDC 00074-6305-60) - discontinued
  • EryPed for oral suspension, 400 mg/5 mL, 200mL (NDC 00074-6305-53) - discontinued
  • EryPed Drops for oral suspension, 100 mg/2.5 mL, 50 mL (NDC 00074-6303-50) - discontinued 

Erythromycin stearate – New NDC Numbers

  • 250 mg Filmtab, 100 count (former Abbott NDC 00074-6346-20) – New (NDC 24338-0106-20)
  • 500 mg Filmtab, 100 count (former Abbott NDC 00074-6316-13) – New (NDC 24338-0108-13) 

Erythromycin stearate – Discontinued Abbott products (not acquired by Arbor)

  • Erythrocin Stearate Filmtab, 250 mg tablets, 500 count (NDC 00074-6346-53) - discontinued

Reason for the Shortage

  • Arbor Pharmaceuticals is the sole supplier of all erythromycin products after acquiring multiple Abbott products. Abbott discontinued several oral erythromycin presentations.1,2
  • Consolidated Midland and Actavis discontinued all erythromycin preparations.3,4

Estimated Resupply Dates

Arbor Pharmaceuticals is the sole supplier of all oral erythromycin products. There is no shortage of product, however NDC numbers have transitioned from the former Abbott NDC numbers. Arbor did not acquire all previous oral erythromycin presentations from Abbott. 

Erythromycin stearate
Arbor Pharmaceuticals has available Erythrocin Stearate 250 mg Filmtab (NDC 24338-0106-20) and 500 mg Filmtab 100 count (NDC 24338-108-13).

Erythromycin base

  • Arbor Pharmaceuticals has available Erythromycin Base Filmtab 250 mg (NDC 24338-0102-13) and 500 mg (NDC 24338-0104-13) 100 count tablets.
  • Arbor Pharmaceuticals has available erythromycin 250 mg (NDC 24338-0120-13) 100 count delayed-release capsules.
  • Arbor Pharmaceuticals has available Ery-Tab 250 mg (NDC 24338-0122-13), 333 mg (NDC 24338-0124-13), and 500 mg (NDC 24338-0126-13) 100 count delayed-release tablets.
  • Arbor Pharmaceuticals has available PCE Dispertab 333 mg 60 count (NDC 24338-0112-60) and 500 mg 100 count (NDC 24338-0114-13) particles in tablets.

Erythromycin ethylsuccinate

  • Arbor Pharmaceuticals has available erythromycin ethylsuccinate 400 mg tablets 100 count (NDC 24338-0110-13) and E.E.S. 400 mg Filmtab 100 count (NDC 24338-0100-13).
  • Arbor Pharmaceuticals has available E.E.S. (erythromycin ethylsuccinate) 200 mg/5 mL 100 mL (NDC 24338-0134-02) and 200 mL (NDC 24338-0136-10) granules for oral suspension.
  • Arbor Pharmaceuticals has available EryPed (erythromycin ethylsuccinate) 400 mg/5mL 100 mL (NDC 24338-0130-13) and 200 mg/5 mL 100 mL (NDC 24338-0132-13) granules for oral suspension.

Implications for Patient Care

  • Oral erythromycin is an antiinfective medication used to treat a variety of bacteria and other infections.5-11 Usual dosing for the various erythromycin preparations are listed in the following table. Length of therapy and optimal dosing is based on patient specific characteristics along with type and severity of infection.
  • No single agent may be substituted for erythromycin for all patients. Base choice of therapy on specific patient characteristics.
  • Multiple preparations of erythromycin have been developed to improve absorption of erythromycin base.12
  • Erythromycin ethylsuccinate 400 mg is equivalent to erythromycin 250 mg as stearate or base.5-11

Table. Dosing for Erythromycin Preparations5-11 

Drug

Adult Dose

Pediatric Dose

Erythromycin Stearate

Erythromycin Base

Erythromycin Base Delayed Release Tablets (Ery-Tab) and Capsules

PCE (erythromycin base as particles)

Usual Starting Dose

250 mg every 6 hours

OR

333 mg every 8 hours*

OR

500 mg every 12 hours

 

Maximum Dose

4 grams/day

Twice daily dosing not recommended in doses >1 gram/day

*333 mg presentation available as PCE and Ery-Tab only

Usual Starting Dose

30-50 mg/kg/day in divided doses

Maximum Dose

May double dose if needed not to exceed 4 grams/day

Erythromycin Ethylsuccinate including EryPed

Usual Starting Dose

400 mg every 6 hours*

 

Maximum Dose

4 grams of erythromycin base/day

 

*400 mg erythromycin ethylsuccinate = 250 mg erythromycin base or stearate

Twice daily dosing not recommended in doses >1 gram/day

Usual Starting Dose

 (doses may be given every 6-12 hours)

Under 10 lbs: 30-50 mg/kg/day or 15-25 mg/lb/day

10-15 lbs: 200 mg/day

16-25 lbs: 400 mg/day

26-50 lbs: 800 mg/day

51-100 lbs: 1200 mg/day

>100 lbs: 1600 mg/day

Maximum Dose

May double dose if needed 


Safety

Avoid switching between products if possible to minimize potential underdosing or overdosing.

Alternative Agents & Management

No single agent may be substituted for erythromycin for all patients. Base choice of therapy on specific patient characteristics.

Related Shortages

References

  1. Abbott Laboratories (personal communications). March 11, 2011.
  2. Arbor Pharmaceuticals (personal communications). March 11, 14, and 30, and April 1, 20, and 21 2011.
  3. Consolidated Midland, Corp. (personal communications). March 11, 2011.
  4. Actavis (personal communications). March 11, 2011.
  5. Erythromycin ethylsuccinate tablets (E.E.S. Filmtab) product information. North Chicago, IL: Abbott Laboratories, June 2009.
  6. Erythromycin ethylsuccinate for oral suspension (EryPed.) product information. North Chicago, IL: Abbott Laboratories, November 2008.
  7. Erythromycin base delayed-release tablets (Ery-Tab) product information. North Chicago, IL: Abbott Laboratories, April 2010.
  8. Erythromycin stearate tablets (Erythrocin Stearate Filmtab) product information. North Chicago, IL: Abbott Laboratories, June 2009.
  9. Erythromycin base tablets (Erythromycin Base Filmtab) product information. North Chicago, IL: Abbott Laboratories, June 2009.
  10. Erythromycin delayed-release capsules product information. North Chicago, IL: Abbott Laboratories, June 2009.
  11. Erythromycin particles in tablet (PCE Dispertab Tablets) product information. North Chicago, IL: Abbott Laboratories, April 2010.
  12. Sivapalasingam S, Steigbigel NH. Macrolides, clindamycin, and ketolides. In: Mandel, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. Mandel GL, Bennett JE, Dolin R, Eds. Philadelphia, PA. Churchill Livingstone Elsevier. 2010: 427-448.

Updated

Updated April 21, 2011 by Erin R. Fox, PharmD, Manager, Drug Information Service. Created March 11, 2011, by Michelle Wheeler, PharmD, Drug Information Specialist. Copyright 2011, Drug Information Service, University of Utah, Salt Lake City, UT.

Hide